食管癌术前放化疗中心脏与肺受照剂量对总生存的影响:CALGB 80803事后分析
该研究对CALGB 80803(Alliance)前瞻性研究进行事后分析,评估食管癌术前放化疗中心脏和肺受照剂量与总生存(OS)的关系,并分析IMRT对方案剂量约束依从性的影响。结果显示多数患者IMRT计划满足总肺和心脏剂量约束,心脏V30 Gy≤21%与OS改善相关,多因素分析中肺V10 Gy>42%和心脏V30 Gy>21%均与更差OS相关。
要点
- 多因素分析:肺V10 Gy>42%(HR 1.71)和心脏V30 Gy>21%(HR 1.86)与更差OS相关。
核心结论
- 最小化肺低剂量体积(V10 Gy)和心脏V30 Gy与显著生存获益相关。
- 设计食管癌放疗计划时应考虑总肺V10 Gy≤42%、心脏V30 Gy≤21%,并优先选用IMRT而非3D-CRT。
研究设计与样本
- CALGB 80803(Alliance)前瞻性研究的事后分析,共225例患者接受诱导化疗,209/225(92.8%)有放疗模式数据。
- 方案规定的剂量约束为:总肺V10 Gy≤40%、V20 Gy≤20%、V30 Gy≤15%、V40 Gy≤10%;心脏V30 Gy≤30%。
- 事后分析计算了最能区分OS的剂量切点。
主要发现
- 127/209(60.9%)接受IMRT治疗。
- 方案剂量约束依从率分别为:总肺V10 Gy 162/209(77.5%)、V20 Gy 179/209(85.6%)、V30 Gy 207/209(99.0%)、V40 Gy 208/209(99.5%)、心脏V30 Gy 158/209(75.6%)。
关键数值与推荐
- 方案规定总肺V10 Gy≤40%、V20 Gy≤20%、V30 Gy≤15%、V40 Gy≤10%,心脏V30 Gy≤30%。
- 事后分析提示总肺V10 Gy≤42%和心脏V30 Gy≤21%与生存获益相关。
临床怎么用
- 食管癌放疗计划设计时应尽量将总肺V10 Gy控制在≤42%、心脏V30 Gy控制在≤21%。
- 优先采用IMRT而非3D-CRT以降低心脏V30 Gy等剂量参数。
局限性
- 本研究为CALGB 80803的事后分析,剂量切点为事后计算,需前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Although technical advances have allowed for reduced radiation doses to the lungs and heart when treating esophageal cancer, doses to these organs cannot yet be eliminated completely. We conducted a post hoc analysis of CALGB 80803 (Alliance) to evaluate whether the radiation doses delivered to the heart and lungs in a prospective study with robust quality assurance were associated with overall survival (OS), and we assessed the impact of intensity modulated radiation therapy (IMRT) on adherence with protocol-specified dose constraints. METHODS AND MATERIALS: Protocol-specified dose constraints were based on standard of care guidelines: total lung V10 Gy ≤ 40%, V20 Gy ≤ 20%, V30 Gy ≤ 15%, V40 Gy ≤ 10%; heart V30 Gy ≤ 30%. Post hoc dose cutpoints were calculated that best differentiated OS. RESULTS: A total of 225 patients underwent induction chemotherapy, where radiation modality data were available for 209/225 (92.8%); 127/209 (60.9%) were treated with IMRT. Adherence rates were high for each of the protocol-specified dose constraints: 162/209 (77.5%), 179/209 (85.6%), 207/209 (99.0%), 208/209 (99.5%), and 158/209 (75.6%); total lung: V10 Gy, V20 Gy, V30 Gy, V40 Gy, and heart V30 Gy, respectively. The heart V30 Gy ≤ 21% (P = .016) was associated with improved OS. Among patients with heart V30 Gy ≤ 21%, 8.5% and 32.3% received 3-dimensional conformal radiation therapy (3D-CRT) and IMRT, respectively (P < .001). Mean heart V30 Gy was lower in the IMRT versus the 3D-CRT group (24.7 vs 35.6; P < .001). On multivariable analysis, lung V10 Gy > 42% (hazard ratio [HR], 1.71; P = .017) and heart V30 Gy > 21% (HR, 1.86; P = .013) were associated with worse OS. CONCLUSIONS: Most patients on CALGB 80803 (Alliance) were treated with IMRT plans that met protocol-specified dose constraints for total lung and heart. Minimizing low dose volume to the lungs (V10 Gy) and minimizing heart V30 Gy were associated with a significant survival benefit. Total lung V10 Gy ≤ 42% and heart V30 Gy ≤ 21%, and utilization of IMRT over 3D-CRT, should be considered when designing radiation plans for patients with esophageal cancer.
引用
- Lehrer EJ, Geyer S, Goodrich A, et al. The Impact of Lung and Heart Radiation Dose During Preoperative Chemoradiation on Overall Survival in Esophageal Cancer-A Post Hoc Analysis of CALGB 80803 (Alliance). Int J Radiat Oncol Biol Phys. 2026. PMID: 41653999. doi:10.1016/j.ijrobp.2026.01.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。